Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

Delayed Quote. Delayed  - 09/27 05:35:07 pm
2.64 EUR   -4.00%
09/08 VALNEVA : Announces Signing of Marketing & Distribution Agreement fo..
09/01 VALNEVA : Reports Strong Revenue Growth and Positive EBITDA in H1201..
08/31 VALNEVA : Reports Strong Revenue Growth and Positive EBITDA in H1 Co..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA SE
09/08 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus` F..
09/01 VALNEVA : Reports Strong Revenue Growth and Positive EBITDA in H12016
08/31 VALNEVA : Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the..
08/31 VALNEVA : Reports Strong Revenue Growth and Positive EBITDA in H12016
08/26VALNEVA SE : half-yearly earnings release
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus&rs..
08/25 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus' F..
07/26 VALNEVA SE : Announces Successful Completion of Phase II for Clostridium Diffici..
07/25 VALNEVA SE : Announces Successful Completion of Phase II for Clostridium Diffici..
07/14 VALNEVA : European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials (€)
Sales 2016 101 M
EBIT 2016 -8,17 M
Net income 2016 -12,9 M
Debt 2016 31,3 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 550,00
EV / Sales 2016 2,35x
EV / Sales 2017 1,98x
Capitalization 205 M
More Financials
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,20 €
Spread / Average Target 53%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Franck Grimaud Chief Executive Officer
Thomas Lingelbach President-Management Board
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-30.53%231
INCYTE CORPORATION-17.87%16 687
CELLTRION, INC.--.--%11 639
LONZA GROUP AG11.83%9 948
QUINTILES TRANSNATIONA..16.08%9 402
SEATTLE GENETICS, INC.26.05%7 828
More Results